-
Endo Wins Citi Upgrade On Positive Catalysts, Cellulite Treatment Opportunity
Wednesday, June 27, 2018 - 3:41pm | 387Read More...Endo International PLC (NASDAQ: ENDP) is now trading at a favorable risk-reward profile and investors should be constructive on the stock, according to Citi. The Analyst Citi's Liav Abraham upgraded Endo International from Neutral to Buy with a price target lifted from $7 to $11. The...
-
Why Is Teva Falling? Competition
Wednesday, October 4, 2017 - 9:10am | 400Read More...Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were under heavy selling pressure Wednesday morning after the U.S. Food and Drug Administration granted approval for a rival product. The FDA granted approval to Mylan N.V. (NASDAQ: MYL) to sell a generic version of Teva's Copaxone...
-
What Approval For Generic Copaxone Means For Mylan
Wednesday, October 4, 2017 - 8:27am | 330Read More...Shares of Mylan N.V. (NASDAQ: MYL) traded higher by more than 13 percent Wednesday morning after the U.S. Food and Drug Administration granted approval for the company's generic version of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s Copaxone. Copaxone, a therapy that is intended...
-
Citi Weighs In On The 'Turmoil At Teva'
Tuesday, February 7, 2017 - 11:17am | 525Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Monday after the bell that its president and CEO Erez Vigodman will step down, effective immediately. The company also said its chairman since January 2015 Yitzhak Peterburg will assume the role of president and CEO on an interim...
-
Citi: Buy Horizon Pharma
Monday, November 28, 2016 - 11:35am | 275Read More...Citi has resumed coverage of Horizon Pharma PLC (NASDAQ: HZNP) with a Buy rating on favorable risk-reward profile and valuation support from orphan franchise. The ratings action comes ahead of pivotal data by Actimmune in Friederich’s Ataxia (FA) in late December. The outcome of this trial is...
-
Citi Downgrades Zoetis, Cites Valuation
Friday, June 10, 2016 - 9:39am | 244Read More...Zoetis Inc (NYSE: ZTS) has been meaningfully outperforming specialty pharma peers year-to-date. Citi’s Liav Abraham downgraded the company from Buy to Neutral, while raising the price target from $46 to $50. Upside Unlikely While maintaining a constructive stance on Zoetis’ fundamentals...
-
Citi Maintains Its Constructive Stance On Allergan
Wednesday, May 11, 2016 - 9:01am | 299Read More...Citi has maintained its Buy rating on Allergan plc Ordinary Shares (NYSE: AGN), saying the performance of the core brands "should not be overlooked." Allergan's first-quarter adjusted earnings of $3.04 per share topped the Street's estimate of $3.01. The company's adjusted top line grew 48.1...
-
It's Not Over For Teva Just Yet After J-Code Rejection, Citi Says
Wednesday, April 20, 2016 - 11:47am | 245Read More...The request by Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) for a separate J-code for Bendeka, the low-volume, short-infusion formulation of Treanda, has been preliminarily rejected by CMS. Citi’s Liav Abraham maintained a Buy rating for the company, with a price target of $75....
-
Is Allergan Worth Over $300 Without Pfizer?
Wednesday, April 6, 2016 - 11:57am | 310Read More...Allergan plc Ordinary Shares (NYSE: AGN) plummeted this week as news broke that Pfizer Inc. (NYSE: PFE) and Allergan will be terminating their proposed merger. The stock may have taken a hit, but a pair of Wall Street analysts believe that there’s plenty of value in a stand-alone Allergan...
-
2 Pharma Stocks To Hide In While Drug Pricing Fears Play Out
Tuesday, September 29, 2015 - 1:37pm | 387Read More...Drug pricing remains a concern within the pharmaceutical sector. Liav Abraham of Citi commented in a note on Monday that recent negative headlines are "unhelpful" to investor sentiment. Abraham suggested investors can "hide" in Allergan PLC (NYSE: AGN) and Teva Pharmaceutical Industries Ltd (ADR...
-
Citi Asks: Is A Mylan-Perrigo Merger Smart?
Thursday, April 9, 2015 - 9:36am | 188Read More...Citi issued an industry update after reports that Mylan NV (NASDAQ: MYL) proposed to acquire Perrigo Company (NYSE: PRGO) for $205 per share. Citi rates Mylan as Neutral with a $54 target price. Analysts Liav Abraham and Timothy Li wrote, "Mylan has indicated its intent to continue to pursue...
-
And The Winner From The Mylan-Perrigo Merger Is... Teva?
Thursday, April 9, 2015 - 9:16am | 270Read More...In a report published Wednesday, Citigroup analyst Liav Abraham commented on a Mylan NV (NASDAQ: MYL) and Perrigo Company plc (NYSE: PRGO) combination, noting that a bid from Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) is still possible, but challenging. According to Abraham, if Teva is...
-
Does Teva Pharmaceutical's New Executive Hint At A Coming M&A Deal?
Tuesday, March 24, 2015 - 10:17am | 216Read More...In a report published Monday, Citigroup analyst Liav Abraham hypothesized that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) recent hire of Timothy Wright as Head of Business Development suggests that a "material, potentially transformative transaction is not off the table." Abraham noted that...
-
Citigroup Says Actavis Is Now Worth $360 Per Share (And It's A Buy)
Wednesday, March 11, 2015 - 9:10am | 227Read More...In a report published Tuesday, Citigroup analyst Liav Abraham commented on a recent meeting with Actavis plc's (NYSE: ACT) senior management team in London that increased his confidence in a "swift and successful" integration of Allergan, Inc. Abraham noted that key growth...
-
Citigroup Ponders How Results From Namenda Survey Might Affect Actavis
Tuesday, January 27, 2015 - 10:48am | 141Read More...In a report published Tuesday, Citigroup analyst Liav Abraham reiterated a Buy rating and $310.00 price target on Actavis PLC (NYSE: ACT). In the report, Citigroup noted, “Feedback from a physician survey we conducted confirms our view that the trajectory of ACT's Namenda franchise in 2016 and...
